Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

Safe and Effective Combination of Donor-Derived, Allogeneic CD19/CD22-CAR T Cells with Myeloablative Graft-Engineered Allo-HCT for High-Risk B-ALL

Blood (2024) 144 (Supplement 1): 679.

https://doi.org/10.1182/blood-2024-211959

Published: 2024

Journal Articles

CD22-Directed CAR T-Cell Therapy for Large B-Cell Lymphomas Progressing after CD19-Directed CAR T-Cell Therapy: Continued Durable Remissions at 3-Year Follow-up

Blood (2024) 144 (Supplement 1): 69.

https://doi.org/10.1182/blood-2024-198544

Published: 2024

Journal Articles

Single Institution Analysis of Lymphoma Treatment Related Post-CAR Myeloid Neoplasms

Blood (2024) 144 (Supplement 1): 96.

https://doi.org/10.1182/blood-2024-205378

Published: 2024

Journal Articles

CD22-Directed CAR T-Cell Therapy Achieves Complete Remission in CD19-Directed CAR T-Cell Refractory Follicular and Mantle Cell Lymphoma

Blood (2024) 144 (Supplement 1): 2064.

https://doi.org/10.1182/blood-2024-198489

Published: 2024

Journal Articles

Spatial Characterization of Molecular Pathways Suggests the Dysregulation of LGR5 Expressing Fibroblasts in Patients with sclerodermatous Chronic Graft-Vs-Host Disease

Marjia Afrin, Sahar Nasr, Cristabelle De Souza, Brooke Howitt, Antonia Maria Mueller, Sally Arai, Judith Shizuru, Gerlinde Wernig

Blood (2024) 144 (Supplement 1): 3536.

https://doi.org/10.1182/blood-2024-211863

Published: 2024

Journal Articles

Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy in Octogenarian Patients (Aged ≥ 80) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Blood (2024) 144 (Supplement 1): 386.

https://doi.org/10.1182/blood-2024-201822

Published: 2024

Journal Articles

A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia

Blood (2024) 144 (16): 1689–1698.

https://doi.org/10.1182/blood.2024024952

Published: 2024

Includes: Supplemental data

Journal Articles

CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias

Blood (2023) 142 (Supplement 1): 360.

https://doi.org/10.1182/blood-2023-182522

Published: 2023

Journal Articles

Final Results from Phase 1 Study of Briquilimab, an Anti-CD117 Monoclonal Antibody, in Combination with Low Dose Irradiation and Fludarabine Conditioning, Shows Durable Remissions in Older Adults with Acute Myeloid Leukemia in Complete Remission and Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation

Arpita Gandhi, Andrew Artz, Catherine J. Lee, Ankur Varma, Bart L. Scott, Hye-Sook Kwon, Minyoung Youn, Chikako Yanagiba, Jeyakavitha Arulprakasam, Anne Le, Judith Shizuru, Wendy W Pang, Lori S. Muffly

Blood (2023) 142 (Supplement 1): 470.

https://doi.org/10.1182/blood-2023-185533

Published: 2023

Journal Articles

Radiation and Busulfan-Free Hematopoietic Stem Cell Transplantation Using Briquilimab (JSP191) Anti-CD117 Antibody-Conditioning, Transient Immunosuppression and TCRαβ + T-Cell/CD19 + B-Cell Depleted Haploidentical Grafts in Patients with Fanconi Anemia

Blood (2023) 142 (Supplement 1): 229.

https://doi.org/10.1182/blood-2023-178400

Published: 2023

Journal Articles

Phase 1 Trial Results for Patients with Advanced Hematologic Malignancies Undergoing Reduced Intensity Allogeneic HCT with Orca-T Donor Cell Therapy Product and Single Agent Tacrolimus

Blood (2023) 142 (Supplement 1): 3560.

https://doi.org/10.1182/blood-2023-188162

Published: 2023

Journal Articles

Targeting of CD25+ Activated T Cells in Gvhd-Associated Marrow Suppression and Cytopenias

Tami D. John, Laura Valine, Giulia Barbarito, Hye-Sook Kwon, Sally Arai, Beth Martin-Kool, Radhika Kumari, Judith Shizuru, Jean S. Oak, Robertson Parkman, Alice Bertaina, Kenneth I. Weinberg

Blood (2023) 142 (Supplement 1): 7033.

https://doi.org/10.1182/blood-2023-190968

Published: 2023

Journal Articles

Allogeneic Transplants from HLA-Mismatched Unrelated Donors Using Total Lymphoid Irradiation and Antithymocyte Globulin Conditioning Retain a Low Risk of Graft-Versus-Host Disease and Non-Relapse Mortality with at Least As Potent Anti-Tumor Activity As with Matched Unrelated Donors

Michael A. Spinner, MD, Marcelo Fernandez Vina, PhD, Linda Elder, BA, Sally Arai, MD, Laura Johnston, MD, Everett Meyer, MD PhD, David Miklos, MD PhD, Lori Muffly, MD, Robert S. Negrin, MD, Judith Shizuru, MD PhD, Wen-Kai Weng, MD PhD, Ginna G. Laport, MD, Samuel Strober, MD, Robert Lowsky, MD, Andrew R. Rezvani, MD

Blood (2016) 128 (22): 4669.

https://doi.org/10.1182/blood.V128.22.4669.4669

Published: 2016

Journal Articles

Phase I Study of CD8 Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematologic Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation

Lori S. Muffly, MDMS, Kevin Sheehan, PhD, Randall Armstrong, Keri Tate, PhD, Cynthia Tudisco, Andrew R. Rezvani, MD, David Miklos, MD PhD, Sally Arai, MD, Judith Shizuru, MD PhD, Laura Johnston, Everett Meyer, MD PhD, Wen-Kai Weng, MD PhD, Ginna G. Laport, MD, Robert S Negrin, MD, Sam Strober, Robert Lowsky, MD

Blood (2016) 128 (22): 4615.

https://doi.org/10.1182/blood.V128.22.4615.4615

Published: 2016

Journal Articles

Foxp3 + regulatory T Cells Maintain Bone Marrow Microenvironment for B Cell Differentiation from Hematopoietic Stem Cells

Hidekazu Nishikii, MD PhD, Antonio Pierini, MD, Yasuhisa Yokoyama, MD,PhD, Takaharu Kimura, MD PhD, Hye-Sook Kwon, PhD, Maite Alvarez, PhD, Jeanette Baker, PhD, Judith Shizuru, MD PhD, Joy Wu, MD PhD, Shigeru Chiba, MD, PhD, Robert S. Negrin, MD

Blood (2016) 128 (22): 431.

https://doi.org/10.1182/blood.V128.22.431.431

Published: 2016

Journal Articles

Donor-Derived CIK Cell Infusion As Consolidative Therapy after Non-Myeloablative Allogeneic Transplant in Patients with Myeloid Neoplasms

Blood (2015) 126 (23): 3232.

https://doi.org/10.1182/blood.V126.23.3232.3232

Published: 2015

Journal Articles

Early Infusion Of Donor-Derived CIK Cells As Consolidative Immunotherapy Following Non-Myeloablative Allogeneic Transplantation: Safety and Feasibility

Jonathan Benjamin, MD, PhD, Ginna G Laport, MD, Keri Tate, PhD, Leah Galvez, RN, Randall Armstrong, Kevin Sheehan, PhD, Sally Arai, MD, Robert Lowsky, MD, Laura Johnston, MD, David B. Miklos, MD, PhD, Judith Shizuru, PhD, MD, Wen-Kai Weng, MD, PhD, Robert Negrin, MD

Blood (2013) 122 (21): 899.

https://doi.org/10.1182/blood.V122.21.899.899

Published: 2013

Journal Articles

A Dose Escalation Trial of Imatinib for Steroid Dependent Chronic Graft-Versus-Host Disease with Anti-PDGFRA Antibody Analysis.

George L. Chen, MD, Sally Arai, MD, Mary E.D. Flowers, MD, Joanne Otani, RN, MSN, Ethan C. Cheng, Alex McMillan, PhD, Wen-Kai Weng, MD, PhD, Judith Shizuru, PhD, MD, Laura Johnston, MD, David Miklos, MD, PhD

Blood (2009) 114 (22): 3304.

https://doi.org/10.1182/blood.V114.22.3304.3304

Published: 2009

Journal Articles

Nonmyeloablative Allogeneic HCT From Unrelated Donors for Multiple Myeloma (MM).

Marcello Rotta, MD, Barry E Storer, Thoralf Lange, MD, Michael Pulsipher, MD, Judith Shizuru, MD, PhD, Benedetto Bruno, MD, PhD, Peter A. McSweeney, MD, Edward Agura, MD, Thomas Chauncey, MD, PhD, Frederick R Appelbaum, MD, William Bensinger, MD, Brenda M Sandmaier, MD, Rainer F Storb, George E. Georges, MD, David G Maloney, MD, PhD

Blood (2009) 114 (22): 3391.

https://doi.org/10.1182/blood.V114.22.3391.3391

Published: 2009

Journal Articles

Engraftment Failure After Non-Myeloablative Hematopoietic Stem Cell Transplantation: Donor CD4 Cells Interfere with Residual Host Cells and Can Trigger Rejection of the Graft.

Antonia MS Mueller, Mareike Florek, Judith Shizuru

Blood (2009) 114 (22): 3528.

https://doi.org/10.1182/blood.V114.22.3528.3528

Published: 2009

NARROW

Safe and Effective Combination of Donor-Derived, Allogeneic CD19/CD22-CAR T Cells with Myeloablative Graft-Engineered Allo-HCT for High-Risk B-ALL

CD22-Directed CAR T-Cell Therapy for Large B-Cell Lymphomas Progressing after CD19-Directed CAR T-Cell Therapy: Continued Durable Remissions at 3-Year Follow-up

Single Institution Analysis of Lymphoma Treatment Related Post-CAR Myeloid Neoplasms

CD22-Directed CAR T-Cell Therapy Achieves Complete Remission in CD19-Directed CAR T-Cell Refractory Follicular and Mantle Cell Lymphoma

Spatial Characterization of Molecular Pathways Suggests the Dysregulation of LGR5 Expressing Fibroblasts in Patients with sclerodermatous Chronic Graft-Vs-Host Disease

Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy in Octogenarian Patients (Aged ≥ 80) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia

CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias

Radiation and Busulfan-Free Hematopoietic Stem Cell Transplantation Using Briquilimab (JSP191) Anti-CD117 Antibody-Conditioning, Transient Immunosuppression and TCRαβ + T-Cell/CD19 + B-Cell Depleted Haploidentical Grafts in Patients with Fanconi Anemia

Phase 1 Trial Results for Patients with Advanced Hematologic Malignancies Undergoing Reduced Intensity Allogeneic HCT with Orca-T Donor Cell Therapy Product and Single Agent Tacrolimus

Targeting of CD25+ Activated T Cells in Gvhd-Associated Marrow Suppression and Cytopenias

Allogeneic Transplants from HLA-Mismatched Unrelated Donors Using Total Lymphoid Irradiation and Antithymocyte Globulin Conditioning Retain a Low Risk of Graft-Versus-Host Disease and Non-Relapse Mortality with at Least As Potent Anti-Tumor Activity As with Matched Unrelated Donors

Phase I Study of CD8 Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematologic Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation

Foxp3 + regulatory T Cells Maintain Bone Marrow Microenvironment for B Cell Differentiation from Hematopoietic Stem Cells

Donor-Derived CIK Cell Infusion As Consolidative Therapy after Non-Myeloablative Allogeneic Transplant in Patients with Myeloid Neoplasms

Early Infusion Of Donor-Derived CIK Cells As Consolidative Immunotherapy Following Non-Myeloablative Allogeneic Transplantation: Safety and Feasibility

A Dose Escalation Trial of Imatinib for Steroid Dependent Chronic Graft-Versus-Host Disease with Anti-PDGFRA Antibody Analysis.

Nonmyeloablative Allogeneic HCT From Unrelated Donors for Multiple Myeloma (MM).

Engraftment Failure After Non-Myeloablative Hematopoietic Stem Cell Transplantation: Donor CD4 Cells Interfere with Residual Host Cells and Can Trigger Rejection of the Graft.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only